Type Whole antibody Routes of
administration Intravenous CAS Number 1326232-46-5 | Source Human ATC code none | |
Target Interferon α/β receptor | ||
Anifrolumab is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.
This drug was developed by MedImmune. A Phase II clinical trial was completed in 2016. Two Phase III trials are planned as of August 2016.
Adverse effects
The most common adverse effect in the study was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.
References
Anifrolumab Wikipedia(Text) CC BY-SA